scholarly journals The Danish Multiple Sclerosis Treatment Register

2016 ◽  
Vol Volume 8 ◽  
pp. 549-552 ◽  
Author(s):  
Melinda Magyari ◽  
Nils Koch-Henriksen ◽  
Per Sørensen
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Register ◽  
Multiple Sclerosis Treatment

scholarly journals The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis

2018 ◽  
Vol 4 (4) ◽  
pp. 205521731881318 ◽  
Author(s):  
IC Hasselbalch ◽  
HB Søndergaard ◽  
N Koch-Henriksen ◽  
A Olsson ◽  
H Ullum ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Propensity Score ◽  
Clinical Information ◽  
Neutrophil To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Cell Counts ◽  
Unit Increase ◽  
White Blood Cell Counts ◽  
Treatment Register ◽  
Multiple Sclerosis Treatment

Background Subtypes of white blood cell counts are known biomarkers of systemic inflammation and a high neutrophil-to-lymphocyte ratio (NLR) has been associated with several autoimmune diseases. Few studies have investigated the NLR in multiple sclerosis (MS). Objective To examine the association between NLR, MS and disability measured by the MS severity score (MSSS). Methods Patients were included from the Danish Multiple Sclerosis Biobank. Information on patient NLR was obtained just before their first treatment and clinical information was provided by the Danish Multiple Sclerosis Treatment Register. Information on NLR from controls was collected from the Danish Blood Donor Study. Patients and controls were 1:2 propensity score matched by baseline confounders. Results Propensity score matching left 740 of 743 MS patients and 1420 of 4691 controls for further analyses. Odds-ratio (OR) was 3.64 (95% confidence interval 2.87–4.60, p < 0.001) for MS disease per unit increase of logarithmically transformed NLR (ln-NLR), corresponding to an OR of 2.68 for each doubling of NLR. Mean NLR was 2.12 for patients and 1.72 for controls ( p < 0.001). Ln-NLR correlated weakly with patient MSSS ( R2 = 0.019, p = 0.008). Conclusion Patients with early MS had increased levels of NLR compared to healthy controls and NLR was weakly correlated with MSSS.

scholarly journals Clinical efficacy and safety of alemtuzumab in postmarketing practice

2019 ◽  
pp. 56-62
Author(s):  
N. V. Khachanova
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Drug Efficacy ◽  
Safety Monitoring ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Treatment Benefit ◽  
Dosing Schedule ◽  
The World ◽  
Multiple Sclerosis Treatment

Clinical trials confirm alemtuzumab efficacy for multiple sclerosis treatment in terms of both conventional measures and combined criteria such as NEDA (no evidence of disease activity). However, established drug efficacy and convenient dosing schedule are balanced by the risk of serious adverse events. Therefore, it is necessary to inform physicians about the benefits of alemtuzumab therapy along with the pattern of its safety profile.The present review provides the analysis of alemtuzumab real-world studies in Europe, USA and other parts of the world. The information obtained can help physicians to prescribe and administer the drug properly and to perform effective safety monitoring for early detection of adverse events and saving the maximum treatment benefit for the patient.

Smoking affects the interferon beta treatment response in multiple sclerosis

Neurology ◽  
2018 ◽  
Vol 90 (7) ◽  
pp. e593-e600 ◽  
Author(s):  
Eva R. Petersen ◽  
Annette B. Oturai ◽  
Nils Koch-Henriksen ◽  
Melinda Magyari ◽  
Per S. Sørensen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Relapse Rate ◽  
Interferon Beta ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
End Of Treatment ◽  
Relapsing Remitting ◽  
Observational Cohort ◽  
Treatment Register ◽  
Relapsing Remitting Multiple Sclerosis

ObjectiveTo investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)–DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (NAT1) variant rs7388368A.MethodsDNA from 834 IFN-β–treated patients with RRMS from the Danish Multiple Sclerosis Biobank was extracted for genotyping. Information about relapses from 2 years before the start of treatment to either the end of treatment or the last follow-up visit was obtained from the Danish Multiple Sclerosis Treatment Register. Smoking information came from a comprehensive questionnaire.ResultsWe found that the relapse rate in patients with RRMS during IFN-β treatment was higher in smokers compared to nonsmokers, with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 1.021–1.416, p = 0.027) and with an IRR increase of 27% per pack of cigarettes per day (IRR 1.27, 95% CI 1.056–1.537, p = 0.012). We found no association or interaction with HLA and the NAT1 variant.ConclusionIn this observational cohort study, we found that smoking is associated with increased relapse activity in patients with RRMS treated with IFN-β, but we found no association or interaction with HLA or the NAT1 variant.

Sign in / Sign up

Export Citation Format

Share Document